Oppenheimer Asset Management Inc. Acquires 71,283 Shares of Novo Nordisk A/S $NVO

Oppenheimer Asset Management Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 565,007 shares of the company’s stock after buying an additional 71,283 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $31,352,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC grew its stake in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the 3rd quarter valued at $30,000. NewSquare Capital LLC lifted its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Finally, Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $37,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NVO shares. HSBC reissued a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating for the company. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. CICC Research began coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $47.71 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The firm has a fifty day moving average of $53.61 and a 200-day moving average of $53.73. The firm has a market capitalization of $213.03 billion, a price-to-earnings ratio of 13.75 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 52.74%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.